Since 2009, several clinical trial results reported findings that will likely change the way patients with acute myeloid leukemia (AML), multiple myeloma, breast cancer as well as children with high-risk neuroblastoma are treated. In addition, the discovery of certain gene alterations in children with acute lymphoblastic leukemia (ALL) has uncovered potential new targets for therapeutic approaches in this disease.